
Cocrystal Pharma COCP
$ 0.95
3.26%
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ CAPITAL |
Shares |
11.3 M |
Market Cap[1] |
$ 10.7 M |
EBITDA (LTM) |
$ -8.95 M |
P/E (LTM) |
-1.448718 |
P/S (LTM) |
- |
EPS (LTM) |
-0.78 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Lipocine
LPCN
|
$ 1.44 | -1.37 % | $ 7.85 M | Nasdaq Global Select Market | ||
|
Provention Bio
PRVB
|
- | - | $ 2.37 B | Nasdaq Global Select Market | ||
|
Poseida Therapeutics
PSTX
|
- | - | $ 857 M | Nasdaq Global Select Market | ||
|
Liquidia Corporation
LQDA
|
$ 42.65 | 7.46 % | $ 3.67 B | Nasdaq Capital Market | ||
|
Annovis Bio
ANVS
|
$ 1.0 | -0.07 % | $ 20.6 M | NYSE American | ||
|
Checkmate Pharmaceuticals
CMPI
|
- | - | $ 231 M | Nasdaq Global Market | ||
|
Atara Biotherapeutics
ATRA
|
$ 8.59 | -8.91 % | $ 108 M | Nasdaq Global Select Market,SPB | ||
|
Lexicon Pharmaceuticals
LXRX
|
$ 1.42 | -4.7 % | $ 516 M | Nasdaq Global Select Market | ||
|
Reata Pharmaceuticals
RETA
|
- | - | $ 6.29 B | Nasdaq Global Market,SPB | ||
|
PolarityTE
PTE
|
- | -0.82 % | $ 1.78 M | Nasdaq Capital Market | ||
|
Moleculin Biotech
MBRX
|
$ 6.5 | 10.36 % | $ 7.7 M | Nasdaq Global Select Market | ||
|
Mirum Pharmaceuticals
MIRM
|
$ 80.39 | -3.26 % | $ 4.04 B | Nasdaq Global Select Market | ||
|
MediciNova
MNOV
|
$ 1.39 | -1.31 % | $ 68.2 M | Nasdaq Global Market | ||
|
Merck & Co.
MRK
|
$ 145.27 | -1.34 % | $ 363 B | NYSE,SPB | ||
|
Maravai LifeSciences Holdings
MRVI
|
$ 7.32 | 3.54 % | $ 1.06 B | Nasdaq Global Select Market | ||
|
Virpax Pharmaceuticals
VRPX
|
- | -45.12 % | $ 2.85 M | Nasdaq Global Select Market | ||
|
Axsome Therapeutics
AXSM
|
$ 145.04 | -7.07 % | $ 7.22 B | Nasdaq Global Market,SPB | ||
|
Matinas BioPharma Holdings
MTNB
|
$ 1.71 | 0.88 % | $ 9.36 M | NYSE American | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
$ 4.05 | -1.94 % | $ 53.9 M | Nasdaq Global Market | ||
|
Stealth BioTherapeutics Corp
MITO
|
- | - | $ 23.9 M | Nasdaq Global Select Market | ||
|
Neurocrine Biosciences
NBIX
|
$ 142.7 | -0.41 % | $ 14.2 B | Nasdaq Global Select Market,SPB | ||
|
Satsuma Pharmaceuticals
STSA
|
- | -0.9 % | $ 36.5 M | Nasdaq Global Market | ||
|
BioCardia
BCDA
|
$ 0.92 | -0.83 % | $ 6.13 M | Nasdaq Global Select Market | ||
|
Kodiak Sciences
KOD
|
$ 87.63 | 2.16 % | $ 4.66 B | Nasdaq Global Market,SPB | ||
|
BioCryst Pharmaceuticals
BCRX
|
$ 7.65 | -1.67 % | $ 1.61 B | Nasdaq Global Select Market | ||
|
SpringWorks Therapeutics
SWTX
|
- | - | $ 3.48 B | Nasdaq Global Select Market,SPB | ||
|
Nektar Therapeutics
NKTR
|
$ 37.22 | -3.7 % | $ 628 M | Nasdaq Global Select Market,SPB | ||
|
Nkarta
NKTX
|
$ 1.79 | 2.87 % | $ 132 M | Nasdaq Global Select Market | ||
|
NanoViricides
NNVC
|
$ 1.4 | 0.72 % | $ 28.3 M | NYSE American | ||
|
Trevena
TRVN
|
- | -46.58 % | $ 31.8 M | Nasdaq Capital Market | ||
|
Nurix Therapeutics
NRIX
|
$ 25.34 | -0.67 % | $ 2.2 B | Nasdaq Global Select Market,SPB | ||
|
Denali Therapeutics
DNLI
|
$ 18.41 | -1.34 % | $ 3.18 B | Nasdaq Global Select Market,SPB | ||
|
Oncorus
ONCR
|
- | -8.54 % | $ 3.19 M | Nasdaq Global Market | ||
|
OncoSec Medical Incorporated
ONCS
|
- | 31.87 % | $ 1.61 M | Nasdaq Global Select Market | ||
|
Y-mAbs Therapeutics
YMAB
|
- | - | $ 382 M | Nasdaq Global Select Market,SPB | ||
|
BioDelivery Sciences International
BDSI
|
- | -4.8 % | $ 255 M | Nasdaq Global Select Market | ||
|
Novan
NOVN
|
- | -24.84 % | $ 2.64 M | Nasdaq Capital Market | ||
|
Novo Nordisk A/S
NVO
|
$ 39.05 | -1.01 % | $ 173 B | NYSE | ||
|
Navidea Biopharmaceuticals
NAVB
|
- | -2.99 % | $ 2.47 M | NYSE American | ||
|
BioLineRx Ltd.
BLRX
|
$ 2.05 | -0.65 % | $ 5.05 B | Nasdaq Capital Market | ||
|
Bristol-Myers Squibb Company
BMY
|
$ 61.48 | -2.41 % | $ 125 B | NYSE,SPB | ||
|
NextCure
NXTC
|
$ 4.98 | 5.51 % | $ 14.2 M | Nasdaq Global Select Market | ||
|
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | ||
|
BELLUS Health
BLU
|
- | - | $ 2.47 B | Nasdaq Global Select Market | ||
|
Ocugen
OCGN
|
$ 0.74 | -6.37 % | $ 231 M | Nasdaq Capital Market | ||
|
Ocular Therapeutix
OCUL
|
$ 6.5 | -1.66 % | $ 1.22 B | Nasdaq Global Select Market | ||
|
bluebird bio
BLUE
|
- | - | $ 546 M | Nasdaq Global Select Market,SPB | ||
|
Intra-Cellular Therapies
ITCI
|
- | - | $ 13.6 B | Nasdaq Global Select Market,SPB | ||
|
Oragenics
OGEN
|
$ 0.41 | 3.11 % | $ 884 K | NYSE American | ||
|
Atossa Therapeutics
ATOS
|
$ 2.6 | -4.41 % | $ 22.4 M | Nasdaq Capital Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.